Time For LUFA? Lab-Developed Test Policy Will Be Key Piece Of 2017 FDA Law
This article was originally published in RPM Report
FDA is hoping to set up yet another user fee program—this one for lab-developed test oversight—when the next user fee legislation is enacted in 2017. The labs aren’t ready to negotiate yet, but the issue is going to be an important area for biopharma to monitor as the transition to personalized medicine continues.
You may also be interested in...
FDA’s decision to hold off on finalizing its guidance on oversight of lab-developed tests is an acknowledgement of the new US political dynamics after the Nov. 8 elections. It may also be an important signal of where early attention will fall at FDA after the transition: on the devices, not drugs.
An Institute of Medicine workshop on companion diagnostics suggests that regulatory standards are evolving at FDA to encourage companion diagnostic development. But almost everything else is still a challenge.
US FDA’s workshop to discuss new ideas to assess the impact of the opioid REMS comes after the industry collaboration behind the REMS has deemed the task essentially impossible.